Sanctuary Advisors LLC Acquires 16,511 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Sanctuary Advisors LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 80.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,039 shares of the biopharmaceutical company’s stock after purchasing an additional 16,511 shares during the period. Sanctuary Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,120,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. International Assets Investment Management LLC bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ bought a new position in Halozyme Therapeutics in the second quarter valued at approximately $49,000. GAMMA Investing LLC increased its position in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the last quarter. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $57,000. Finally, FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics in the third quarter valued at $65,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Wells Fargo & Company lowered Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $58.00 to $62.00 in a research note on Monday, October 7th. JMP Securities increased their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $61.11.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at $9,254,244.56. This represents a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 30,000 shares of company stock worth $1,621,800. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $46.84 on Thursday. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a market cap of $5.96 billion, a price-to-earnings ratio of 15.51, a P/E/G ratio of 0.43 and a beta of 1.23. The stock’s fifty day moving average price is $51.20 and its two-hundred day moving average price is $54.14.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.